/
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
The business is unprofitable at the operating level (-1141.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 146.7% YoY with margins expanding 2299.1pp.
Negative free cash flow of -$90M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$10M
▲ +146.7% YoY
Net Income (TTM)
-$204M
▼ -98.6% YoY
Op. Margin
-1141.13%
▲ +2299.1pp YoY
ROIC
-106.98%
▲ +18.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$117M
▼ -17.0% YoY
Op. Cash Flow (TTM)
-$115M
▼ -28.8% YoY
Net Debt
$42M
Cash & Equiv.
$56M
5Y CAGR: -21.3%
Continue Research